Levetiracetam

Limits on what this shows

• Key negative/null findings: A separate study (cited in secondary literature, not independently opened in this review and therefore not scored) reportedly found levetiracetam given after prolonged status epilepticus did not protect against mitochondrial dysfunction in a rodent model, an explicit contradiction of the Gibbs 2006 finding under different timing; flagged here as a named counter-result even though it could not be verified firsthand.
• At-risk subgroups: None identified for harm. The MELAS association, if causal, would be most relevant to patients with diagnosed mitochondrial disease, a population this dossier does not treat as generalizable to typical epilepsy patients.
• Counter-evidence on record: The Zhang 2019 mortality benefit is a clinical outcome in a specific mitochondrial-disease population, not a direct measurement of mitochondrial burden in a general epilepsy population, and is reported here as context rather than as proof, consistent with the rule against filing a clinical outcome as a nutrient/category finding under another name.

Regulatory status

Not labeled. No mitochondrial toxicity language in the FDA prescribing information.

Population evidence

Gibbs, Walker, Cock, Epilepsia 2006 (rat perforant-pathway status epilepticus model, Tier B animal): levetiracetam (200 or 1000 mg/kg) did not suppress electrographic seizures but "protects against mitochondrial dysfunction," preserving glutathione levels and enzyme activities otherwise depleted after status epilepticus. Rogers et al., Frontiers in Neurology 2014 (Tier B in vitro, C17.2 neuronal stem cells and mouse splenocytes): levetiracetam increased mitochondrial membrane potential in NGF-treated neuronal cells at 1.5 uM, 15 uM, and 0.15 mM, but decreased it in splenocytes, a cell-type-dependent, not uniformly protective, effect. Zhang et al., Chinese Medical Journal 2019 (retrospective cohort, Tier A human but outcome-level, not a direct mitochondrial biomarker): 102 MELAS (mitochondrial encephalomyopathy) patients with seizures, 48 on levetiracetam versus 54 not; mortality 8.3% versus 37.0% (p=.001), hazard ratio 0.24 (95% CI 0.08 to 0.74, p=.013). Authors propose an SV2A-linked mitochondrial membrane potential mechanism, not directly measured in this cohort.

Mechanism

Proposed but not confirmed in humans: SV2A, the drug's seizure-control target, localizes partly to mitochondrial and vesicular membranes, and in vitro exposure changes mitochondrial membrane potential in a cell-type-dependent way.

Counter-evidence held on record

This is a reverse-direction, plausibly protective signal, not a burden. It should never be used to suggest levetiracetam requires mitochondrial-support supplementation; if anything, the mechanistic literature points away from a need for it. Cite the MELAS finding only as population-specific context, not as a general-epilepsy claim.

Limits on what this shows

• Key negative/null findings: Mindreanu et al., International Journal of Molecular Sciences 2026 (systematic review, 11 human studies, 297 participants with analyzable biomarker data): "No body of human evidence identified by this review is of sufficient validity to support or to refute a redox effect of levetiracetam." Within that review, paraoxonase-1, arylesterase, and total antioxidant capacity findings ran in the opposite direction (reduced antioxidant capacity, not simply elevated peroxidation) in some included studies, and MDA findings across the full review were explicitly mixed, not uniformly elevated.
• At-risk subgroups: Only pediatric data exists at the Tier A level (Haznedar, ages not further specified beyond "children"). No adult monotherapy oxidative-stress cohort was located.
• Counter-evidence on record: The systematic review above is itself the primary counter-evidence: same drug, larger combined sample, explicit conclusion of insufficient and inconsistent evidence. No other levetiracetam-specific human study replicating the elevated-MDA finding was located across PubMed, Europe PMC, Semantic Scholar, or OpenAlex searches.

Regulatory status

Not labeled. FDA prescribing information contains no oxidative-stress or redox-marker language for levetiracetam.

Population evidence

Haznedar et al., Epilepsy Research 2019: case-control, 26 children on therapeutic-dose levetiracetam monotherapy for 6+ months, 25 on valproic acid, 26 healthy controls. Malondialdehyde (MDA, lipid peroxidation) and 8-hydroxy-2-deoxyguanosine (8-OHdG, DNA oxidative damage) were significantly elevated in the levetiracetam group versus controls; MDA correlated positively with ammonia and 8-OHdG within that group.

Mechanism

Not established for the direction of harm. Levetiracetam has no known pro-oxidant chemistry; the authors explicitly call for further study of mechanism. Separately, an animal status-epilepticus model (Gibbs 2006) found levetiracetam preserved glutathione and antioxidant enzyme activity, the opposite direction, so any mechanism proposed has to explain both findings, not just one.

Counter-evidence held on record

This is not an indication to supplement antioxidants on levetiracetam. No dose of any antioxidant supplement has drug-specific evidence in this population, and the same-drug systematic review says biomarkers should not be used to guide levetiracetam prescribing or monitoring at all. Do not present this as a settled finding; present it as a single bounded signal that a larger, same-drug evidence review found unconfirmed.

Limits on what this shows

• Key negative/null findings: None located specific to levetiracetam; no drug-stratified copper study for levetiracetam alone was found across PubMed, Europe PMC, or OpenAlex searches.
• At-risk subgroups: Cannot be determined from a non-stratified cohort.
• Counter-evidence on record: None located; the entry is graded down from orange specifically because the cohort mixes five drugs without per-drug breakdown, which fails this protocol's cohort test for attributing the effect to levetiracetam.

Regulatory status

Not labeled. No copper language in the FDA prescribing information.

Population evidence

Talat, Ahmed, Mohammed, Neurosciences (Riyadh) 2015: 90 epileptic children on long-term therapy with sodium valproate, carbamazepine, phenytoin, clonazepam, or levetiracetam (levetiracetam confirmed present in the drug list), versus 90 matched healthy controls. Serum copper 180.1 plus or minus 32.4 microg/dL in patients versus 114.5 plus or minus 18.5 microg/dL in controls (p<.001), an elevation, not a deficiency.

Mechanism

Not established for levetiracetam specifically. Copper is an acute-phase reactant and can rise with chronic inflammatory or seizure-related states independent of any specific drug mechanism; this study cannot separate a levetiracetam effect from a disease-state effect or an effect of the other four drugs in the pooled cohort.

Counter-evidence held on record

This is an elevation, not a deficiency; if it does apply to levetiracetam, copper supplementation would be the wrong direction entirely, not the remedy. No copper dose recommendation is or should be attached to this entry. Never present this as copper deficiency risk. The measured direction in the only study found is the opposite.

Limits on what this shows

• Key negative/null findings: The null finding above is itself the key result and is the primary reason this entry exists at all.
• At-risk subgroups: None identified.
• Counter-evidence on record: A human observational study on gut microbiota in drug-resistant epilepsy (Riva et al., Epilepsia 2025) could not be opened during this review (PubMed Central returned a bot-verification page on repeated attempts); it is therefore excluded from the evidence base rather than cited, and it is unknown whether it stratifies by levetiracetam specifically.

Regulatory status

Not labeled.

Population evidence

Dop, Auvin, Mondot, Lepage, Ilhan, ISME Communications 2024 (Tier B, in vitro fecal microcosm model, not human in vivo): fecal microcosms from 4 pediatric donors exposed to levetiracetam, carbamazepine, or water control across repeated cycles. At cycle 7, "no genera were significantly different between the LEV and Water-Ctrl" groups, in contrast to carbamazepine, which "had the most substantial impact on the structure and metabolism of the feces-derived microcosms."

Mechanism

Consistent with the drug's non-hepatic, non-enzyme-inducing profile and with its minimal effect on gut flora-relevant bile acid or pH handling; no absorption-interference or bile-acid-sequestration mechanism is present per the Step 2 mechanism screen.

Counter-evidence held on record

This is reassuring, drug-specific, in vitro only, and from a 4-donor model; it should not be overstated as "levetiracetam is proven safe for the microbiome," only that the one drug-specific test located found no effect where a comparator drug in the same experiment showed a large one.

Limits on what this shows

• Key negative/null findings: Neither pediatric cohort found a hemoglobin or hematocrit decrease at any time point; the labeled adjunctive-trial decrease was not replicated in either monotherapy cohort.
• At-risk subgroups: Leukopenia/neutropenia risk (not oxygen-delivery risk) is the consistent, replicated signal across all three sources and belongs in the monitoring panel, not this entry, per this protocol's rule against filing a drug's own labeled toxicity as a nutrient-category finding.
• Counter-evidence on record: The label and the two pediatric monotherapy studies are each other's counter-evidence; this entry exists specifically to disclose that conflict rather than average it away.

Regulatory status

Labeled. FDA prescribing information, Warnings and Precautions 5.8: levetiracetam "can cause decreases in white blood cell (WBC), neutrophil, and red blood cell (RBC) counts; decreases in hemoglobin and hematocrit; and increases in eosinophil counts." In controlled adjunctive trials, 3.2% on levetiracetam versus 1.8% on placebo showed decreased WBC.

Population evidence

Koc Ucar, Sisli Etfal Hastanesi Tip Bulteni 2022: 64 children, idiopathic epilepsy, levetiracetam monotherapy, CBC at baseline, 3 to 6 months, and 12 months. Hemoglobin, hematocrit, mean corpuscular volume, and platelet measures increased significantly by 12 months; WBC, neutrophils, and lymphocytes decreased. Dilber et al., Turkish Journal of Pediatric Disease 2022: 114 children, newly diagnosed idiopathic epilepsy, levetiracetam monotherapy, followed to 3 years. Hemoglobin and hematocrit showed a significant increase; absolute lymphocyte count and absolute neutrophil count decreased significantly (p<.001); liver function unchanged.

Mechanism

Not established in either direction. The labeled decrease derives from short-term adjunctive randomized trials in mixed adult and pediatric populations already on other AEDs. The two cohorts showing increase are longer-term (1 to 3 year) monotherapy follow-up in newly diagnosed children, a population in which resolving seizure burden, reduced inflammation, or normal growth could plausibly raise hemoglobin independent of any direct levetiracetam effect on erythropoiesis (confounding by indication, not excluded in either study).

Counter-evidence held on record

Do not present either direction as established. This is a genuine gap between short-term adjunctive-trial labeling and longer-term pediatric monotherapy follow-up, most plausibly reflecting different populations and designs rather than a single true drug effect in either direction. Routine CBC monitoring (already indicated for the labeled leukopenia risk) will catch either pattern; no iron or hematinic supplementation is indicated by this entry in either direction.

Limits on what this shows

• Key negative/null findings: None identified specific to ATP output; the search returned no drug-specific human ATP-synthesis studies to either confirm or refute an effect.
• At-risk subgroups: None identified.
• Counter-evidence on record: None located; see Overlap map for the shared-source relationship with Mitochondrial burden, which this entry's evidence base should not be read as independently confirming.

Regulatory status

Not labeled.

Population evidence

Rogers et al., Frontiers in Neurology 2014 (Tier B in vitro): the same mitochondrial membrane potential dataset cited under Mitochondrial burden above; authors explicitly conclude "both neuronal and non-neuronal anti-epileptic activities of levetiracetam involve control over energy metabolism." No independent ATP-flux or oxygen-consumption assay in levetiracetam-exposed human cells was located across PubMed, Europe PMC, Semantic Scholar, or OpenAlex searches using multiple phrasings ("levetiracetam ATP production," "levetiracetam oxidative phosphorylation," "levetiracetam cellular respiration").

Mechanism

Indirect: membrane potential is the immediate substrate for ATP synthase activity, but membrane potential change is not itself an ATP output measurement, and this entry is graded down from what the mitochondrial burden entry supports specifically because of that gap.

Counter-evidence held on record

Do not present this as evidence of impaired energy production. The only human-adjacent data (Zhang 2019, cited under Mitochondrial burden) point toward benefit, not deficit, and no CoQ10, carnitine, or "mitochondrial cocktail" supplement claim for this drug was found circulating to rebut or support.